Survodutide Delivery: Comparing Syringe vs. Pen for Bioequivalence
Background
Survodutide (BI 456906) is an investigational drug being developed for conditions like obesity. Ensuring consistent drug delivery is crucial for patient safety and efficacy, especially for chronic conditions requiring long-term treatment. This Phase 1 study addresses the critical need to confirm if different administration devices for Survodutide deliver the drug equivalently within the body.
Results
This Phase 1 study is currently active but not yet recruiting, meaning results are pending completion in June 2026. The primary objective is to determine the bioequivalence of Survodutide formulation A (pre-filled syringe) and Survodutide formulation B2 (pre-filled pen) in the 56 enrolled participants. > The ultimate finding will confirm if these two distinct delivery methods result in comparable drug exposure and absorption within the body, which is essential for interchangeable use. This assessment will involve comparing key pharmacokinetic parameters such as maximum drug concentration (Cmax) and area under the curve (AUC) between the two formulations.
Why It Matters
Establishing bioequivalence between different delivery devices for Survodutide is a critical step for its future clinical development and patient accessibility. If the pre-filled syringe and pen deliver the drug equivalently, it offers flexibility in manufacturing and patient choice, potentially improving adherence to treatment for obesity. This could pave the way for Survodutide to be available in multiple convenient forms, accelerating its path towards broader clinical use in human trials. This study is foundational for subsequent Phase 2 and Phase 3 trials, ensuring consistent drug performance regardless of the chosen injector.